Principal Financial Group Inc. Buys Shares of 59,594 Keros Therapeutics, Inc. $KROS

Principal Financial Group Inc. purchased a new position in Keros Therapeutics, Inc. (NASDAQ:KROS) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 59,594 shares of the company’s stock, valued at approximately $658,000. Principal Financial Group Inc. owned approximately 0.30% of Keros Therapeutics at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently made changes to their positions in the stock. Financial Management Professionals Inc. bought a new stake in shares of Keros Therapeutics during the 4th quarter worth $29,000. Caitong International Asset Management Co. Ltd increased its stake in Keros Therapeutics by 254.6% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,624 shares of the company’s stock valued at $33,000 after acquiring an additional 1,166 shares during the last quarter. Tower Research Capital LLC TRC increased its stake in Keros Therapeutics by 149.2% in the second quarter. Tower Research Capital LLC TRC now owns 3,153 shares of the company’s stock valued at $42,000 after acquiring an additional 1,888 shares during the last quarter. New York State Common Retirement Fund raised its position in Keros Therapeutics by 264.1% during the second quarter. New York State Common Retirement Fund now owns 10,616 shares of the company’s stock valued at $142,000 after purchasing an additional 7,700 shares in the last quarter. Finally, The Manufacturers Life Insurance Company raised its position in Keros Therapeutics by 8.6% during the second quarter. The Manufacturers Life Insurance Company now owns 12,451 shares of the company’s stock valued at $166,000 after purchasing an additional 988 shares in the last quarter. Hedge funds and other institutional investors own 71.56% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently issued reports on KROS. Wall Street Zen cut Keros Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, May 16th. Weiss Ratings cut Keros Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a report on Friday, May 15th. Finally, Zacks Research cut Keros Therapeutics from a “hold” rating to a “strong sell” rating in a report on Wednesday. Three equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $20.40.

Insider Activity

In other news, Director Alpna Seth sold 2,625 shares of Keros Therapeutics stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $10.72, for a total value of $28,140.00. Following the transaction, the director owned 9,767 shares in the company, valued at approximately $104,702.24. The trade was a 21.18% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Julius Knowles sold 2,625 shares of the business’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $10.73, for a total value of $28,166.25. Following the completion of the sale, the director directly owned 10,958 shares of the company’s stock, valued at approximately $117,579.34. This trade represents a 19.33% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 8,425 shares of company stock valued at $89,994. 12.60% of the stock is currently owned by insiders.

Keros Therapeutics Stock Performance

KROS stock opened at $10.07 on Friday. The firm has a market cap of $199.29 million, a P/E ratio of -3.35 and a beta of 0.97. The firm’s fifty day moving average is $10.70 and its 200 day moving average is $12.70. Keros Therapeutics, Inc. has a 52 week low of $9.69 and a 52 week high of $22.55.

Keros Therapeutics (NASDAQ:KROS) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($1.21) earnings per share for the quarter, missing the consensus estimate of ($1.02) by ($0.19). Keros Therapeutics had a negative return on equity of 17.04% and a negative net margin of 256.60%.The business had revenue of $0.37 million during the quarter, compared to the consensus estimate of $1.93 million. As a group, analysts forecast that Keros Therapeutics, Inc. will post -5.19 EPS for the current year.

About Keros Therapeutics

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-?) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.